Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of “Buy” by Analysts

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) has earned a consensus recommendation of “Buy” from the six brokerages that are currently covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $6.25.

A number of brokerages recently commented on TNYA. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Tenaya Therapeutics in a research report on Tuesday, September 2nd. Chardan Capital reiterated a “buy” rating and issued a $9.00 target price on shares of Tenaya Therapeutics in a research report on Thursday, August 7th. Finally, Wall Street Zen upgraded shares of Tenaya Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th.

Tenaya Therapeutics Stock Up 6.8%

Shares of NASDAQ:TNYA opened at $1.41 on Friday. The stock has a market cap of $229.80 million, a PE ratio of -1.47 and a beta of 3.07. The company’s fifty day moving average is $1.00 and its 200 day moving average is $0.70. Tenaya Therapeutics has a 52 week low of $0.36 and a 52 week high of $4.01.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its earnings results on Wednesday, August 6th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.06. Sell-side analysts anticipate that Tenaya Therapeutics will post -1.35 EPS for the current year.

Institutional Investors Weigh In On Tenaya Therapeutics

Large investors have recently added to or reduced their stakes in the company. Nuveen LLC bought a new stake in Tenaya Therapeutics in the 1st quarter worth $129,000. Northern Trust Corp grew its holdings in Tenaya Therapeutics by 6.2% in the 4th quarter. Northern Trust Corp now owns 472,479 shares of the company’s stock worth $676,000 after acquiring an additional 27,632 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in Tenaya Therapeutics in the 1st quarter worth $33,000. Deutsche Bank AG grew its holdings in Tenaya Therapeutics by 304.1% in the 4th quarter. Deutsche Bank AG now owns 129,319 shares of the company’s stock worth $185,000 after acquiring an additional 97,318 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its holdings in Tenaya Therapeutics by 25.2% in the 4th quarter. Nuveen Asset Management LLC now owns 345,192 shares of the company’s stock worth $494,000 after acquiring an additional 69,377 shares during the last quarter. Institutional investors own 90.54% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.